Microsoft Word - 05_2007101800709203_FullPaper_查.doc
... potentially take place during forest aging. 2. METHODOLOGY 2.1 Radiative transfer models: PROFLIGHT During ... masses of coarse woody debris propagate throughout the canopy. And: 2) the spatial arrangements of woody ... potentially take place during forest aging. 2. METHODOLOGY 2.1 Radiative transfer models: PROFLIGHT During ... masses of coarse woody debris propagate throughout the canopy. And: 2) the spatial arrangements of woody ... Microsoft Word - 05_2007101800709203_FullPaper_ 查.doc ...
Essay – Page 2 – Xenotheka
... Essay – Page 2 – Xenotheka Search for: Toggle navigation Home Collaboration On Xenotheka Folders ... of art from the founding of the French ... Continue Reading → Xenotheka on August 23, 2018 ← 1 2 3 ... Essay – Page 2 – Xenotheka ... https://xenotheka.delbeke.arch.ethz.ch/tag/essay/page/ 2/ ... Essay – Page 2 – Xenotheka ...
Das Transplantationszentrum im 2
... Das Transplantationszentrum im 2 Annual Report Transplant Centre University Hospital Zurich 2014 ... Annual Report TPLZ 2014 Seite 2 von 26 1. The Transplant Centre in its 7th year ... Das Transplantationszentrum im 2 ... Das Transplantationszentrum im 2 Annual Report Transplant Centre University Hospital Zurich 2014 ... Das Transplantationszentrum im 2 ...
Das Transplantationszentrum im 2
... Das Transplantationszentrum im 2 Annual Report TPLZ 1 Annual Report Transplant Centre University ... Hospital Zurich 2015 Annual Report TPLZ 2 1. The Transplant Centre in its 8th year ... Das Transplantationszentrum im 2 ... Das Transplantationszentrum im 2 Annual Report TPLZ 1 Annual Report Transplant Centre University ... Das Transplantationszentrum im 2 ...
Elecsys® SARS-CoV-2 Antigen
... individuals with a cobas® SARS-CoV- 2 Target 2 Ct value <30 was 94.5 % ( 95 %, CI two-sided: 90.4 – 97.2 % [189 ... . Immunoassay for the qualitative detection of the SARS-CoV- 2 nucleocapsid antigen The Elecsys® SARS-CoV- 2 ... cobas ® SARS-CoV- 2 Target 2 Ct value <30 was 94.5 % ( 95 %, CI two-sided: 90.4 – 97.2 % [189/200]). View ... Elecsys® SARS-CoV- 2 Antigen ... Elecsys® SARS-CoV- 2 Antigen ...
Elecsys® SARS-CoV-2 Antigen
... individuals with a cobas® SARS-CoV- 2 Target 2 Ct value <30 was 94.5 % ( 95 %, CI two-sided: 90.4 – 97.2 % [189 ... . Immunoassay for the qualitative detection of the SARS-CoV- 2 nucleocapsid antigen The Elecsys® SARS-CoV- 2 ... -CoV- 2 Target 2 Ct value <30 was 94.5 % ( 95 %, CI two-sided: 90.4 – 97.2 % [189/200]). View Full Table ... close Cohort cobas® SARS-CoV- 2 Ct <30 cobas® SARS-CoV- 2 Ct ≥30 N Non-reactive Sensitivity ( 95 % CI§) N ... Elecsys® SARS-CoV- 2 Antigen ...
Elecsys® SARS-CoV-2 Antigen
... cobas® SARS-CoV- 2 Target 2 Ct value <30 was 94.5 % ( 95 %, CI two-sided: 90.4 – 97.2 % [189/200]). (0.2 ... SARS-CoV- 2 nucleocapsid antigen The Elecsys® SARS-CoV- 2 Antigen assay uses monoclonal antibodies ... -CoV- 2 Target 2 Ct value <30 was 94.5 % ( 95 %, CI two-sided: 90.4 – 97.2 % [189/200]). Se hela tabellen ... close Cohort cobas® SARS-CoV- 2 Ct <30 cobas® SARS-CoV- 2 Ct ≥30 N Non-reactive Sensitivity ( 95 % CI§) N ... Elecsys® SARS-CoV- 2 Antigen ...
Elecsys® SARS-CoV-2 Antigen
... individuals with a cobas® SARS-CoV- 2 Target 2 Ct value <30 was 94.5 % ( 95 %, CI two-sided: 90.4 – 97.2 % [189 ... . Immunoassay for the qualitative detection of the SARS-CoV- 2 nucleocapsid antigen The Elecsys® SARS-CoV- 2 ... cobas ® SARS-CoV- 2 Target 2 Ct value <30 was 94.5 % ( 95 %, CI two-sided: 90.4 – 97.2 % [189/200]). View ... Elecsys® SARS-CoV- 2 Antigen ... Elecsys® SARS-CoV- 2 Antigen ...
Elecsys® Anti-SARS-CoV-2
... session has expired. Please log in again. Elecsys® Anti-SARS-CoV- 2 Immunoassay intended for qualitative ... detection of antibodies to SARS-CoV- 2 in human serum and plasma. For use under the Emergency Use ... 2019 were tested with the Elecsys ® Anti-SARS-CoV- 2 assay. Cohort N Reactive Specificity % ( 95 % CI ... Elecsys® Anti-SARS-CoV- 2 ... Elecsys® Anti-SARS-CoV- 2 ...
cobas® SARS-CoV-2 Test
... The cobas® SARS-CoV- 2 Test provides reliable and high-quality results for clinical decision-making for ... the improved management of COVID-19 patients and to reduce the risk of SARS-CoV- 2 infection ... samples TARGET POSITIVE AGREEMENT NEGATIVE AGREEMENT LoD ( 95% Probit) SARS-CoV- 2 100% 100% 0.007 TCID 50 ... cobas® SARS-CoV- 2 Test ... cobas® SARS-CoV- 2 Test ...
